Rhabdomyosarcoma
R Dasgupta, J Fuchs, D Rodeberg - Seminars in pediatric surgery, 2016 - Elsevier
A malignant tumor of striated muscle origin, rhabdomyosarcoma (RMS) is a childhood tumor
that has benefited from nearly 30 years of multimodality therapy, culminating in a> 70 …
that has benefited from nearly 30 years of multimodality therapy, culminating in a> 70 …
p53 as a target for the treatment of cancer
MJ Duffy, NC Synnott, PM McGowan, J Crown… - Cancer treatment …, 2014 - Elsevier
Abstract TP53 (p53) is the most frequently mutated gene in cancer, being altered in
approximately 50% of human malignancies. In most, if not all, cancers lacking mutation, wild …
approximately 50% of human malignancies. In most, if not all, cancers lacking mutation, wild …
TP53 in bone and soft tissue sarcomas
Genomic and functional study of existing and emerging sarcoma targets, such as fusion
proteins, chromosomal aberrations, reduced tumor suppressor activity, and oncogenic …
proteins, chromosomal aberrations, reduced tumor suppressor activity, and oncogenic …
[HTML][HTML] Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine
C Fiorini, M Cordani, C Padroni, G Blandino… - … et Biophysica Acta (BBA …, 2015 - Elsevier
Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer-related deaths
worldwide; PDAC is characterized by poor prognosis, resistance to conventional …
worldwide; PDAC is characterized by poor prognosis, resistance to conventional …
Update on rhabdomyosarcoma
R Dasgupta, DA Rodeberg - Seminars in pediatric surgery, 2012 - Elsevier
Rhabdomyosarcoma (RMS) is a malignant childhood tumor of mesenchymal origin that
currently has a greater than 70% overall 5-year survival. Multimodality treatment is …
currently has a greater than 70% overall 5-year survival. Multimodality treatment is …
[HTML][HTML] GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis
Rhabdomyosarcoma (RMS) typically arises from skeletal muscle. Currently, RMS in patients
with recurrent and metastatic disease have no successful treatment. The molecular …
with recurrent and metastatic disease have no successful treatment. The molecular …
The pharmalogical reactivation of p53 function improves breast tumor cell lysis by granzyme B and NK cells through induction of autophagy
M Chollat-Namy, T Ben Safta-Saadoun… - Cell death & …, 2019 - nature.com
Cytotoxic T lymphocytes (CTL) and natural killer cells (NK)-mediated elimination of tumor
cells is mostly dependent on Granzyme B apoptotic pathway, which is regulated by the wild …
cells is mostly dependent on Granzyme B apoptotic pathway, which is regulated by the wild …
[HTML][HTML] Small molecules targeting programmed cell death in breast cancer cells
Targeted chemotherapy has become the forefront for cancer treatment in recent years. The
selective and specific features allow more effective treatment with reduced side effects. Most …
selective and specific features allow more effective treatment with reduced side effects. Most …
2-Styryl-4-aminoquinazoline derivatives as potent DNA-cleavage, p53-activation and in vivo effective anticancer agents
XW Wei, JM Yuan, WY Huang, NY Chen, XJ Li… - European Journal of …, 2020 - Elsevier
Forty-eight analogues of CP-31398, an antitumor agent modulated the mutant p53 gene
were synthesized and their cytotoxicities against four cancer cell lines with different p-53 …
were synthesized and their cytotoxicities against four cancer cell lines with different p-53 …
Modulation of cellular redox parameters for improving therapeutic responses in multiple myeloma
Raised oxidative stress and abnormal redox status are typical features of multiple myeloma
cells, and the identification of the intimate mechanisms that regulate the relationships …
cells, and the identification of the intimate mechanisms that regulate the relationships …